Madison researchers have developed an implantable, battery-free pacemaker that’s charged by a patient’s heartbeat. The device has the potential to last an entire lifetime, reducing the risks and costs associated with replacing devices when their batteries fail.
US drugmakers Merck and Moderna said Wednesday a personalized cancer treatment had shown success in reducing the recurrence of melanoma tumors in a late-stage trial hailed by experts as a “breakthrough.”
Cancer spreading beyond the primary tumor—a process known as metastasis—is responsible for at least two-thirds of cancer deaths. Drugs targeting metastatic progression have largely failed, in part because of the lack of predictive models that would help identify the underlying mechanisms of metastasis.
A compound produced in the body after eating pomegranates improves heart function by up to 80% in a type of heart failure with limited treatment options.
Touting an “exceptional” gastrointestinal safety profile for its oral obesity drug candidate in a study of healthy volunteers, Enveda plans to test the asset in people stopping GLP-1 treatment.
MIT researchers’ approach, which uses naturally occurring sugars as antifreeze, could make it easier for hospitals to deploy this type of cancer treatment.
The approval covers smartSedLine monitor availability in applicable European markets.
WUXI, China, Aug. 19, 2026 /PRNewswire/ — NORROY BIOSCIENCE (NORROY), a clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has granted both Breakthrough Therapy and Fast Track designations to NORROY’s 68Ga-NYM096, a potential radiopharmaceutical imaging agent targeting carbonic anhydrase Ⅸ (CAⅨ) for PET imaging of clear cell renal cell carcinoma (ccRCC).
Each year, roughly 2% to 5% of the population is affected by mitral valve prolapse (MVP) and mitral regurgitation (MR). These conditions can affect the heart’s rhythm and have been linked to sudden cardiac death, particularly in advanced stages of the disease, through the development of abnormal electrical activity. MVP causes the valve to bend backward as the heart contracts, while MR affects the valve’s ability to close fully, leading to blood leaking backward.
During cancer treatment, the same brain tumor can be treated with the same anticancer drug, but the effect can differ from patient to patient. A Korean research team has developed a chip that recreates a patient’s own tumor cells together with the surrounding peritumoral vascular environment, making it possible to predict patient-specific treatment responses in advance.